Cancer Council Victoria | Victorian Cancer Trials Link

A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma

Clinical summary

The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.

Conditions

This trial is treating patients with Mesothelioma

Trial Acronym
CheckMate743

Trial Identifiers
NCT02899299
CA209-743, 2016-001859-43

Cancer
Lung, Mesothelioma

Age: 18+
Phase: III

For full trial details, visit trials.cancervic.org.au/details/vctl_nct02899299